Evaluating patient risk status
Prognostic implications of NYHA functional class
REVEAL Registry observational analysis: FC III patients who improved to FC I-II within 1 year of enrollment had a significantly better prognosis than patients who remained in FC III or worsened to FC IV.1*
Reveal FC III Patients1 12 months post-enrollment (N=982) | ||
---|---|---|
Improved FC | FC Unchanged | Worsened FC |
27% | 66% | 8% |
Lack of improvement in key clinical indicators correlated with poorer prognosis compared with patients whose indicators improved.2
REVEAL: Nearly 7 in 10 patients may be at risk of a poor prognosis, compared to patients with improving indicators2
*Only patients who obtained a follow-up FC assessment within 1 year of enrollment were included. The first follow-up FC assessment was performed at a mean ± SD of 4 ± 3 months.1
Download the Risk Assessment Sheets to learn more about the ESC/ERS or REVEAL risk criteria.
Consider the consistent treatment guidelines for patients in FC III and FC IV
High Risk per key indicators3-6 |
---|
FC IV, FC III with evidence of rapid progression or other markers of poor prognosis4 |
Worsening Disease despite treatment3-6 |
---|
FC III with evidence of disease progression4 |
Inadequate Clinical Response to current treatment3-6 |
---|
FC III with evidence of poor prognosis despite treatment4 |
The Guidelines Agree: Consider Parenteral Therapy | |||
---|---|---|---|
2009 ACCF/AHA Consensus3 |
2013 5th World Symposium6 |
2014 CHEST Treatment Recommendations4 |
2015 ESC/ERS Treatment Guidelines5 |
ACCF=American College of Cardiology Foundation; AHA=American Heart Association; ERS=European Respiratory Society; ESC=European Society of Cardiology; FC=functional class; NYHA=New York Heart Association; PAH=pulmonary arterial hypertension; REVEAL=Registry to Evaluate Early and Long-Term PAH Disease Management; SD=standard deviation.